免疫抑制剤の世界市場レポート 2025年

免疫抑制剤の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR13.2％で488億8,000万米ドルに成長します。予測期間の成長は、標的治療と精密医療、生物製剤とバイオシミラーの進歩、免疫療法の組み合わせ、遺伝子治療と免疫調節、ドラッグデリバリーの革新に起因すると考えられます。予測期間における主な動向としては、適応拡大、規制と安全性への配慮、精密医療へのアプローチ、遠隔医療と遠隔モニタリング、バイオシミラーとジェネリック医薬品などが挙げられます。

免疫抑制剤市場の成長は、臓器不全の増加により、臓器移植、特に腎移植と肝移植の普及が進んでいることが主因です。特に、米国腎臓基金（American Kidney Fund）は2022年6月、米国の移植待機者数が10万6,000人を超え、その87％が腎臓移植を待っていると報告しました。このような臓器移植例の急増は、免疫抑制剤市場の成長にとって重要な促進要因になると予想されます。

免疫抑制剤市場は、自己免疫疾患の事例が増加していることから、成長する見込みです。健康な細胞、組織、臓器を攻撃する異常な免疫反応を特徴とする自己免疫疾患は増加傾向にあります。免疫抑制剤は、関節リウマチのような自己免疫疾患の管理に有益であり、症状を緩和し、病気の進行を遅らせる。重要な例として、2023年6月に米国疾病予防管理センターが発表したデータでは、米国の成人5,440万人が関節炎と診断されており、この数字は2040年までに7,800万人に達すると予想されています。さらに、2022年11月の国連の世界人口見通しデータでは、65歳以上の世界人口に占める割合が、2022年の10％から2050年には16％に上昇すると予測されています。このように、特に高齢化社会における自己免疫疾患の有病率の増加は、市場における免疫抑制剤の需要を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界免疫抑制剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の免疫抑制剤市場：成長率分析
• 世界の免疫抑制剤市場の実績：規模と成長, 2019-2024
• 世界の免疫抑制剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界免疫抑制剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の免疫抑制剤市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• モノクローナル抗体（mAbs）
• カルシニューリン阻害剤
• mTOR阻害剤
• 抗増殖剤
• その他の薬物クラス
• 世界の免疫抑制剤市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臓器移植
• 自己免疫疾患
• 非自己免疫性炎症疾患
• 世界の免疫抑制剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の免疫抑制剤市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• メチルプレドニゾロン
• デキサメタゾン
• 世界の免疫抑制剤市場モノクローナル抗体（mAbs）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗TNF薬
• 抗CD20剤
• 抗IL-6薬
• 世界の免疫抑制剤市場カルシニューリン阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シクロスポリン
• タクロリムス
• 世界の免疫抑制剤市場mTOR阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• シロリムス
• エベロリムス
• 世界の免疫抑制剤市場抗増殖剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アザチオプリン
• ミコフェノール酸モフェチル
• 世界の免疫抑制剤市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 共刺激遮断薬
• JAK阻害剤

第7章 地域別・国別分析

• 世界の免疫抑制剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の免疫抑制剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 免疫抑制剤市場：競合情勢
• 免疫抑制剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi SA
• Bristol-Myers Squibb Co.
• Mylan Laboratories Inc.
• Teva Pharmaceuticals USA Inc.
• Astellas Pharma Inc.
• Sandoz Inc.
• Aurobindo Pharma Limited
• Hikma Pharmaceuticals plc
• Intas Pharmaceuticals Ltd.
• Zydus Lifesciences Limited
• Glenmark Pharmaceuticals Ltd.
• Fresenius Kabi USA
• Lupin Pharmaceuticals Inc.
• Strides Pharma Inc.
• Accord Healthcare Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 免疫抑制剤市場2029：新たな機会を提供する国
• 免疫抑制剤市場2029：新たな機会を提供するセグメント
• 免疫抑制剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Immunosuppressants are medications used to prevent the immune system from attacking healthy cells, primarily to prevent transplant rejection and manage autoimmune diseases. Careful monitoring is necessary due to their potency and potential side effects.

Key classes of drugs in this market include corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, among others. Monoclonal antibodies are produced by cloning a single white blood cell and are traceable back to that parent cell. These medications are indicated for organ transplantation, autoimmune disorders, and non-autoimmune inflammatory diseases. They are distributed through hospital pharmacies, retail pharmacies, and online channels.

The immunosuppressants market research report is one of a series of new reports from The Business Research Company that provides immunosuppressants market statistics, including the immunosuppressants industry's global market size, regional shares, competitors with an immunosuppressants market share, detailed immunosuppressants market segments, market trends and opportunities, and any further data you may need to thrive in the immunosuppressants industry. This immunosuppressants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The immunosuppressants market size has grown rapidly in recent years. It will grow from $25.94 billion in 2024 to $29.72 billion in 2025 at a compound annual growth rate (CAGR) of 14.6%. The growth in the historic period can be attributed to transplant medicine advancements, drug development and innovation, regulatory approvals, rise in transplant surgeries, clinical efficacy and safety.

The immunosuppressants market size is expected to see rapid growth in the next few years. It will grow to $48.88 billion in 2029 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to targeted therapies and precision medicine, advancements in biologics and biosimilars, immunotherapy combinations, gene therapy and immunomodulation, drug delivery innovations. Major trends in the forecast period include expanded indications, regulatory and safety considerations, precision medicine approaches, telehealth and remote monitoring, biosimilars and generics.

The growth of the immunosuppressant market is primarily attributed to the increasing prevalence of organ transplant procedures, particularly kidney and liver transplants, driven by the rising incidences of organ failure. Notably, the American Kidney Fund reported in June 2022 that the national transplant waiting list in the US would exceed 106,000 individuals, with 87% of them awaiting kidney transplants. This surge in organ transplantation cases is expected to be a key driver for the growth of the immunosuppressant market.

The immunosuppressant market is poised for growth due to the escalating instances of autoimmune diseases. Autoimmune diseases, characterized by abnormal immune responses attacking healthy cells, tissues, and organs, are on the rise. Immunosuppressant medications prove beneficial in managing autoimmune conditions such as rheumatoid arthritis, offering relief from symptoms and slowing down disease progression. A significant example is the data from the Centers for Disease Control and Prevention in June 2023, indicating that 54.4 million adults in the US were diagnosed with arthritis, a figure expected to reach 78 million by 2040. Moreover, the United Nations' World Population Prospect data in November 2022 projected a rise in the share of the global population aged 65 and above from 10% in 2022 to 16% in 2050. This increasing prevalence of autoimmune diseases, particularly in the aging population, is anticipated to drive the demand for immunosuppressants in the market.

The emergence of Phenotypic Personalized Medicine (PPM), employing a hybrid of artificial intelligence and physician intervention, presents a novel approach. Tacrolimus, a widely used immunosuppressant for organ transplant patients, requires frequent monitoring and adjustments during hospitalization. The PPM approach utilizes a computational platform, considering factors such as the patient's historical drug response, concurrent medications, and current liver and kidney data. This approach empowers physicians to identify optimal drug and dose combinations from a range of possibilities, enhancing personalization and effectiveness in drug dosing. Artificial intelligence, through PPM, not only facilitates more personalized drug dosing but also enriches physicians' decision-making capabilities by providing clinical data rather than predicted responses.

Key players in the immunosuppressant market are focusing on developing innovative products, including oral immunosuppressive agents, to improve patient convenience and adherence to treatment. An oral immunosuppressive agent is a medication taken by mouth that reduces the immune system's activity, commonly used to prevent organ rejection in transplant patients or to manage autoimmune disorders. For example, Aurinia Pharmaceuticals Inc., a clinical-stage biopharmaceutical company based in Canada, received approval from the Japanese Ministry of Health, Labour, and Welfare (MHLW) for LUPKYNIS (voclosporin). LUPKYNIS is a novel oral immunosuppressive agent that acts as a second-generation calcineurin inhibitor. It is utilized for treating lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), in Japan. The drug works by inhibiting calcineurin, an enzyme critical for T-cell activation and proliferation, thereby helping to suppress the immune response that leads to kidney inflammation associated with lupus nephritis.

In October 2022, Amgen Inc., a U.S.-based biopharmaceutical and biotechnology company, successfully acquired ChemoCentryx Inc. for $3.7 billion. This strategic acquisition significantly augments Amgen's portfolio of drugs focused on inflammation and nephrology. Additionally, the acquisition brings three therapeutic candidates in the early stages that target chemoattractant receptors, address additional inflammatory conditions, and explore an oral cancer checkpoint. ChemoCentryx, Inc., the acquired company, is a U.S.-based biopharmaceutical firm specializing in the development and commercialization of novel drugs for cancer, autoimmune disorders, and inflammatory illnesses.

Major companies operating in the immunosuppressants market include Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Co., Mylan Laboratories Inc., Teva Pharmaceuticals USA Inc., Astellas Pharma Inc., Sandoz Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals plc, Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Fresenius Kabi USA, Lupin Pharmaceuticals Inc., Strides Pharma Inc., Accord Healthcare Ltd., RPG Life Sciences Limited, Genzyme Transgenics Corp., Apotex Inc.

North America was the largest region in the immunosuppressants market in 2024. The regions covered in the immunosuppressants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the immunosuppressants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The immunosuppressants market consists of sales of induction drugs, maintenance drugs, corticosteroids, and calcineurin inhibitors. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Immunosuppressants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on immunosuppressants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for immunosuppressants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The immunosuppressants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Corticosteroids; Monoclonal Antibodies (mAbs); Calcineurin Inhibitors; mTOR Inhibitors; Anti-Proliferative Agents; Other Drug Classes
• 2) By Indication: Organ Transplantation; Autoimmune Disorders; Non-Autoimmune Inflammatory Diseases
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone
• 2) By Monoclonal Antibodies (mAbs): Anti-TNF Agents; Anti-CD20 Agents; Anti-IL-6 Agents
• 3) By Calcineurin Inhibitors: Cyclosporine; Tacrolimus
• 4) By mTOR Inhibitors: Sirolimus; Everolimus
• 5) By Anti-Proliferative Agents: Azathioprine; Mycophenolate Mofetil
• 6) By Other Drug Classes: Co-Stimulation Blockers; JAK Inhibitors
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F Hoffmann La Roche Ltd.; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Immunosuppressants Market Characteristics

3. Immunosuppressants Market Trends And Strategies

4. Immunosuppressants Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Immunosuppressants Growth Analysis And Strategic Analysis Framework

• 5.1. Global Immunosuppressants PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Immunosuppressants Market Growth Rate Analysis
• 5.4. Global Immunosuppressants Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Immunosuppressants Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Immunosuppressants Total Addressable Market (TAM)

6. Immunosuppressants Market Segmentation

• 6.1. Global Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Monoclonal Antibodies (mAbs)
• Calcineurin Inhibitors
• mTOR Inhibitors
• Anti-Proliferative Agents
• Other Drug Classes
• 6.2. Global Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Organ Transplantation
• Autoimmune Disorders
• Non-Autoimmune Inflammatory Diseases
• 6.3. Global Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Immunosuppressants Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• Dexamethasone
• 6.5. Global Immunosuppressants Market, Sub-Segmentation Of Monoclonal Antibodies (mAbs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anti-TNF Agents
• Anti-CD20 Agents
• Anti-IL-6 Agents
• 6.6. Global Immunosuppressants Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cyclosporine
• Tacrolimus
• 6.7. Global Immunosuppressants Market, Sub-Segmentation Of mTOR Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sirolimus
• Everolimus
• 6.8. Global Immunosuppressants Market, Sub-Segmentation Of Anti-Proliferative Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azathioprine
• Mycophenolate Mofetil
• 6.9. Global Immunosuppressants Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Co-Stimulation Blockers
• JAK Inhibitors

7. Immunosuppressants Market Regional And Country Analysis

• 7.1. Global Immunosuppressants Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Immunosuppressants Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Immunosuppressants Market

• 8.1. Asia-Pacific Immunosuppressants Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Immunosuppressants Market

• 9.1. China Immunosuppressants Market Overview
• 9.2. China Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Immunosuppressants Market

• 10.1. India Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Immunosuppressants Market

• 11.1. Japan Immunosuppressants Market Overview
• 11.2. Japan Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Immunosuppressants Market

• 12.1. Australia Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Immunosuppressants Market

• 13.1. Indonesia Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Immunosuppressants Market

• 14.1. South Korea Immunosuppressants Market Overview
• 14.2. South Korea Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Immunosuppressants Market

• 15.1. Western Europe Immunosuppressants Market Overview
• 15.2. Western Europe Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Immunosuppressants Market

• 16.1. UK Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Immunosuppressants Market

• 17.1. Germany Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Immunosuppressants Market

• 18.1. France Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Immunosuppressants Market

• 19.1. Italy Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Immunosuppressants Market

• 20.1. Spain Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Immunosuppressants Market

• 21.1. Eastern Europe Immunosuppressants Market Overview
• 21.2. Eastern Europe Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Immunosuppressants Market

• 22.1. Russia Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Immunosuppressants Market

• 23.1. North America Immunosuppressants Market Overview
• 23.2. North America Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Immunosuppressants Market

• 24.1. USA Immunosuppressants Market Overview
• 24.2. USA Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Immunosuppressants Market

• 25.1. Canada Immunosuppressants Market Overview
• 25.2. Canada Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Immunosuppressants Market

• 26.1. South America Immunosuppressants Market Overview
• 26.2. South America Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Immunosuppressants Market

• 27.1. Brazil Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Immunosuppressants Market

• 28.1. Middle East Immunosuppressants Market Overview
• 28.2. Middle East Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Immunosuppressants Market

• 29.1. Africa Immunosuppressants Market Overview
• 29.2. Africa Immunosuppressants Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Immunosuppressants Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Immunosuppressants Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Immunosuppressants Market Competitive Landscape And Company Profiles

• 30.1. Immunosuppressants Market Competitive Landscape
• 30.2. Immunosuppressants Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Immunosuppressants Market Other Major And Innovative Companies

• 31.1. Sanofi SA
• 31.2. Bristol-Myers Squibb Co.
• 31.3. Mylan Laboratories Inc.
• 31.4. Teva Pharmaceuticals USA Inc.
• 31.5. Astellas Pharma Inc.
• 31.6. Sandoz Inc.
• 31.7. Aurobindo Pharma Limited
• 31.8. Hikma Pharmaceuticals plc
• 31.9. Intas Pharmaceuticals Ltd.
• 31.10. Zydus Lifesciences Limited
• 31.11. Glenmark Pharmaceuticals Ltd.
• 31.12. Fresenius Kabi USA
• 31.13. Lupin Pharmaceuticals Inc.
• 31.14. Strides Pharma Inc.
• 31.15. Accord Healthcare Ltd.

32. Global Immunosuppressants Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Immunosuppressants Market

34. Recent Developments In The Immunosuppressants Market

35. Immunosuppressants Market High Potential Countries, Segments and Strategies

• 35.1 Immunosuppressants Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Immunosuppressants Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Immunosuppressants Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer